Allergan's poison pill can't stop Valeant from calling shareholders to a vote

Save

Valeant has cleared another hurdle in its quest to buy Allergan. The key next step: a special shareholders meeting, where Valeant will try to shake up the company's board and overturn its acquisition defenses to get a $53 billion deal done Algeria.